000			01788 a2200469 4500
005			20250517140944.0
264		0	_c20170421
008			201704s 0 0 fre d
022			_a1769-6917
024	7		_a10.1016/j.bulcan.2017.01.005 _2doi
040			_aNLM _beng _cNLM
100	1		_aHéquet, Delphine
245	0	0	_a[Androgen receptors in breast cancer: Expression, value and therapeutic prospects]. _h[electronic resource]
260			_bBulletin du cancer _cApr 2017
300			_a363-369 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAbiraterone Acetate _xtherapeutic use
650	0	4	_aAndrogen Antagonists _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBenzamides
650	0	4	_aCyclin-Dependent Kinase 4 _xantagonists & inhibitors
650	0	4	_aCyclin-Dependent Kinase 6 _xantagonists & inhibitors
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKi-67 Antigen _xmetabolism
650	0	4	_aLymphatic Metastasis
650	0	4	_aNeoplasm Proteins _xmetabolism
650	0	4	_aNitriles
650	0	4	_aPhenylthiohydantoin _xanalogs & derivatives
650	0	4	_aPrognosis
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aReceptors, Androgen _xchemistry
650	0	4	_aSteroid 17-alpha-Hydroxylase _xantagonists & inhibitors
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aTriple Negative Breast Neoplasms _xdrug therapy
650	0	4	_aTumor Burden
700	1		_aMzoughi, Slim
700	1		_aRouzier, Roman
700	1		_aGuccione, Ernesto
773	0		_tBulletin du cancer _gvol. 104 _gno. 4 _gp. 363-369
856	4	0	_uhttps://doi.org/10.1016/j.bulcan.2017.01.005 _zAvailable from publisher's website
999			_c26895006 _d26895006